Letter from the Editor EditorProf. Hans-Peter Hartung, Heinrich-Heine-University Düsseldorf, Germany ConferenceMSMilan 2023 4 December, 2023 11:08
Real-world data supports ocrelizumab prior to conception Presented ByDr Wei Yeh, Alfred Health and Monash University, Australia ConferenceMSMilan 2023 4 December, 2023 11:07
MSMilan 2023 Highlights Podcast Presented ByDr Rachel Giles, Medicom ConferenceECTRIMS 2023 31 October, 2023 12:14
Early initiation of highly active treatment associated with a lower risk of SPMS Presented ByDr Christine Lebrun-Frenay, CHU de Nice, France TrialSPAM ConferenceMSMilan 2023 4 December, 2023 11:10
Ocrelizumab more effective than interferon/glatiramer acetate in older MS patients Presented ByDr Yi Chao Foong, Monash University, Australia ConferenceMSMilan 2023 4 December, 2023 11:09
Prioritising high efficacy therapies in children with MS Presented ByDr Nail Benallegue, Nantes University, France ConferenceMSMilan 2023 4 December, 2023 11:10
Omega-3 polyunsaturated fatty acids associated with lower risk of MS activity Presented ByDr Vinicius Schoeps, University of California, CA, USA ConferenceMSMilan 2023 4 December, 2023 11:09
An update on evolving treatment algorithms for NMOSD and MOGAD Presented ByProf. Jeffrey Bennett, University of Colorado, CO, USA ConferenceMSMilan 2023 4 December, 2023 11:09
Switching from rituximab to C5 complement inhibitors is safe in AQP4+ NMOSD TrialPhase 3, PREVENT, CHAMPION-NMOSD ConferenceMSMilan 2023 4 December, 2023 11:08
Rate of grey matter brain atrophy accelerates after menopause Presented ByDr Alyssa Nylander, University of California, CA, USA TrialEPIC ConferenceMSMilan 2023 4 December, 2023 11:09
Real-world data supports ocrelizumab prior to conception Presented ByDr Wei Yeh, Alfred Health and Monash University, Australia ConferenceMSMilan 2023 4 December, 2023 11:07
New insights into the contribution of EBV to MS pathogenesis Presented ByProf. Thomas Berger, Medical University of Vienna, Austria ConferenceMSMilan 2023 4 December, 2023 11:10
COVID-19 infection associated with higher MS relapse rate Presented ByMr David Levitz, Monash University, Australia ConferenceMSMilan 2023 4 December, 2023 11:09
Telerehabilitation effective in improving MS symptoms in patients with moderate disability Presented ByDr Maria Petracca, Sapienza University of Rome, Italy ConferenceMSMilan 2023 4 December, 2023 11:08
Understanding what an MS cure means and what it takes Presented ByProf. Stephen Hauser, University of California, CA, USA ConferenceMSMilan 2023 4 December, 2023 11:08
Progressive brain tissue loss precedes the onset of clinical MS by years Presented ByDr Christina Azevedo, University of Southern California, CA, USA ConferenceMSMilan 2023 4 December, 2023 11:09
Sickness absence rate increases years before clinical onset of MS Presented ByDr Ali Manouchehrinia, Karolinska University, Sweden ConferenceMSMilan 2023 4 December, 2023 11:08
Early intensive treatment enhances long-term clinical outcomes Presented ByDr Pietro Iaffaldano, University of Bari, Italy ConferenceMSMilan 2023 4 December, 2023 11:12
Anti-CD40L antibody safe and effective in a phase 2 study TrialPhase 2 ConferenceMSMilan 2023 4 December, 2023 11:11
Oral glycolipid shows promise in the treatment of MS, especially SPMS Presented ByDr Tomoko Okamoto, National Center Hospital, Tokyo, Japan TrialPhase 2 ConferenceMSMilan 2023 4 December, 2023 11:10
Fenebrutinib shows rapid reduction of new Gd+ T1 lesions Presented ByProf. Amit Bar-Or, University of Pennsylvania, PA, USA TrialPhase 2, FENopta ConferenceMSMilan 2023 4 December, 2023 11:09
Challenges of de-escalation versus discontinuation of highly effective DMTs in older MS patients Presented ByProf. Vincent Van Pesch, UCLouvain, Belgium ConferenceMSMilan 2023 4 December, 2023 11:08
Retinal OCT markers hold promise for early MS diagnosis ConferenceMSMilan 2023 4 December, 2023 11:13
χ-separation can assess the effects of tissue destruction in early MS lesions Presented ByDr Jannis Müller, University of Basel, Switzerland ConferenceMSMilan 2023 4 December, 2023 11:12
High sGFAP levels are associated with disease progression, independent of NfL or relapse activity Presented ByDr Pascal Benkert, University Hospital Basel, Switzerland ConferenceMSMilan 2023 4 December, 2023 11:11
Broad rim lesions correlate with a rapidly progressive MS phenotype Presented ByDr Jussi Lehto, University of Turku, Finland ConferenceMSMilan 2023 4 December, 2023 11:10
Smouldering inflammation detectable even in the earliest stages of MS Presented ByDr Markus Matilainen, University of Turku, Finland ConferenceMSMilan 2023 4 December, 2023 11:09